A randomized study of the influence of proton pump inhibitors on antiplatelet effect by Clopidogrel based on CYP2C19 genotypes

A randomized study of the influence of proton pump inhibitors on antiplatelet effect by Clopidogrel based on CYP2C19 genotypes - CYP2C19, Clopidgrel and Proton Pump Inhibitor Estimation study(CYCLON study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003898

Enrollment

150

Registered

2010-07-20

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina pectoris and myocardial infarction

Interventions

Study patients are randomized into three groups according to proton pump inhibitors administration. a) Rabeprazole 10mg b) Lansoprazole 30mg c) Omeprazole 20mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient with angina pectoris or myocardial infarction, who underwent de novo coronary stent implantation

Exclusion criteria

Exclusion criteria: 1) the patient of severe liver disease 2) the patient of severe renal disease 3) the patient of congenital heart disease 4) the patient of myocardial infarction within 3 months from onset or of severe cardiac function 5) the patient of endocrine disease 6) the patient of malignant or inflammatory disease 7) the patient of severe respiratory disease including idiopathic pulmonary artery hypertension 8) the patient of impaired activities of daily living by neurological or orthopedic disease 9) the patient of severe hypertension 10) the patient who taking corticosteroid or immunosuppressive drug 11) the patient of type 1 diabetes mellitus 12) the patient pregnant or probable of pregnancy 13) the catecholamine injected patient 14) the patient of symptomatic hypotension 15) the patient with left ventricular outflow tract obstruction, hypertrophic obstructive cardiomyopthy or aortic stenosis, effecting hemodynamics significantly 16) the patient who is judged inappropriate for any reason by doctor

Design outcomes

Primary

Measure	Time frame
Inhibitory effect of anti-platelet aggregation estimated by phosphorytation of VASP after administration of clopidgrel and proton pump inhibitors	—

Secondary

Measure	Time frame
relationship between CYP2C19 genotypes and the effect of proton pump inhibitors on anti-platelet aggregation by clopidgrel	—

Countries

Japan

Contacts

Public ContactNoguchi Teruo

National Cerebral and Cardiovascular center Division of cardiology, Department of Medicine

tnoguchi@hsp.ncvc.go.jp06-6833-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026